Bulman, C.A., Bidlow, C.M., Lustigman, S., Cho-Ngwa, F., Williams, D., Rascón Jr., A.A., Tricoche, N., Samje, M., Bell, A., Suzuki, B., Lim, K.C., Supakorndej, N., Supakorndej, P., Wolfe, A.R., Knudsen G. M., Chen, S., Wilson, C., Ang, K-H., Arkin, M., Gut, J., Franklin, C., Marcellino, C., McKerrow, J.H., Debnath, A. and Sakanari, J.A. (2015) Repurposing Auranofin as a Lead Candidate for Treatment of Lymphatic Filariasis and Onchocerciasis. PLoS Neglected Tropical Disease, 9, e0003534.
http://dx.doi.org/10.1371/journal.pntd.0003534

has been cited by the following article:

• TITLE: Synthesis, Molecular Structure and Anti-Onchocercal Studies of 1-(Phthalazin-1(2H)-one)[(Pyridin-2-yl)ethylidene]hydrazone

  AUTHORS: Joseph N. Yong, Felicite Majoumo-Mbe, Moses Samje, Emmanuel N. Nfor

  KEYWORDS: Hydralazine Hydrochloride, Schiff Bases, Anti-Onchocercal Activity

  JOURNAL NAME: International Journal of Organic Chemistry, Vol.6 No.1, March 30, 2016

  ABSTRACT: The novel ligand, 1-(phthalazin-1(2H)-one)[(pyridin-2-yl)ethylidene]hydrazone,(APN), derived from the antihypertensive drug, hydralazine hydrochloride, was synthesized and characterized by spectroscopic methods (IR, 1H NMR). The X-ray crystallographic data indicates that APN has an exocyclic C=N bond on the hydralazine moiety. APN revealed significant anti-onchocercal activity with IC50 values of 0.3125 μg/mL on microfilaria and 10 μg/mL on adult worms compared to the standard drug, ivermectin.